PL2167128T3 - Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v - Google Patents

Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v

Info

Publication number
PL2167128T3
PL2167128T3 PL08784834T PL08784834T PL2167128T3 PL 2167128 T3 PL2167128 T3 PL 2167128T3 PL 08784834 T PL08784834 T PL 08784834T PL 08784834 T PL08784834 T PL 08784834T PL 2167128 T3 PL2167128 T3 PL 2167128T3
Authority
PL
Poland
Prior art keywords
alpha
hybrid antibodies
engineered anti
integrin hybrid
integrin
Prior art date
Application number
PL08784834T
Other languages
English (en)
Inventor
Simon Goodman
Diane Hahn
Francesc Mitjans
Jaume Adan
Kin-Ming Lo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL2167128T3 publication Critical patent/PL2167128T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL08784834T 2007-07-17 2008-07-17 Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v PL2167128T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07013964 2007-07-17
PCT/EP2008/005852 WO2009010290A2 (en) 2007-07-17 2008-07-17 Engineered anti-alpha v- integrin hybrid antibodies
EP08784834A EP2167128B1 (en) 2007-07-17 2008-07-17 Engineered anti-alpha v- integrin hybrid antibodies

Publications (1)

Publication Number Publication Date
PL2167128T3 true PL2167128T3 (pl) 2013-03-29

Family

ID=40029330

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08784834T PL2167128T3 (pl) 2007-07-17 2008-07-17 Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v

Country Status (19)

Country Link
US (1) US8562986B2 (pl)
EP (2) EP2167128B1 (pl)
JP (1) JP5341889B2 (pl)
KR (1) KR101559596B1 (pl)
CN (1) CN101687039B (pl)
AU (1) AU2008277907B2 (pl)
BR (1) BRPI0815567B8 (pl)
CA (1) CA2693863C (pl)
CY (1) CY1113493T1 (pl)
DK (1) DK2167128T3 (pl)
EA (1) EA019485B1 (pl)
ES (1) ES2395799T3 (pl)
HR (1) HRP20120949T1 (pl)
IL (1) IL203269A (pl)
PL (1) PL2167128T3 (pl)
PT (1) PT2167128E (pl)
SI (1) SI2167128T1 (pl)
WO (1) WO2009010290A2 (pl)
ZA (1) ZA201001124B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2368118T3 (da) 2008-12-23 2013-11-25 Merck Patent Gmbh Biomarkører til inhibitorer med anti-angiogen aktivitet
BR112012003686B1 (pt) * 2009-08-19 2021-09-21 Merck Patent Gmbh Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo
ES2683347T3 (es) * 2011-02-11 2018-09-26 Merck Patent Gmbh Anticuerpo anti-integrina alfa-v para el tratamiento de cáncer de próstata
EP3712166A1 (en) * 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP7372025B2 (ja) * 2014-09-17 2023-10-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 固形がんおよび／またはその転移を処置する方法、そのための薬剤、ならびに固形がんおよび／またはその転移処置の臨床転帰を予測する方法
KR20170055540A (ko) 2014-09-17 2017-05-19 메르크 파텐트 게엠베하 뼈 전이 질환 치료 방법, 그에 따른 약제, 및 뼈 전이 질환 치료의 임상 결과 예측 방법
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
MX2018006269A (es) * 2015-11-23 2018-09-05 Merck Patent Gmbh Anticuerpo anti-alfa-v-integrina para el tratamiento de fibrosis y/o trastornos fibroticos.
HK1254295A1 (zh) 2015-11-23 2019-07-19 默克专利股份有限公司 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体
EP3510407A1 (en) 2016-09-08 2019-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN116712540A (zh) 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
SG11201905259SA (en) 2017-02-02 2019-08-27 Merck Patent Gmbh Preferred pairing of antibody domains
CN108948206B (zh) * 2017-05-23 2022-08-23 赵磊 一种抗egfr/pd-1双靶向抗体、其制备方法及用途
JP7543134B2 (ja) 2017-10-03 2024-09-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング システイン操作された抗原結合分子
US11339221B2 (en) * 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020079209A1 (en) 2018-10-19 2020-04-23 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN114366749B (zh) * 2020-10-15 2023-06-30 中国人民解放军海军军医大学 整合素抑制剂在制备治疗肾癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658396B2 (en) * 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
ATE244306T1 (de) * 1994-12-20 2003-07-15 Merck Patent Gmbh Monoklonaler antikörper gegen das alpha-v- integrin
JP3461945B2 (ja) 1994-12-26 2003-10-27 株式会社日本製鋼所 高低圧一体型タービンロータの製造方法
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
JP4279554B2 (ja) * 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
MXPA05005558A (es) 2002-11-26 2005-07-26 Protein Design Labs Inc Anticuerpos quimericos y humanizados para integrina ( 5 ( 1 que modulan la angiogenesis.
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
US7669429B2 (en) 2006-01-19 2010-03-02 Bassler Sr G Scott Rapid food chiller

Also Published As

Publication number Publication date
SI2167128T1 (sl) 2013-01-31
JP2010533480A (ja) 2010-10-28
WO2009010290A3 (en) 2009-04-09
WO2009010290A2 (en) 2009-01-22
BRPI0815567B8 (pt) 2021-05-25
PT2167128E (pt) 2013-01-24
JP5341889B2 (ja) 2013-11-13
DK2167128T3 (da) 2012-12-03
AU2008277907B2 (en) 2013-08-22
EP2167128A2 (en) 2010-03-31
US8562986B2 (en) 2013-10-22
IL203269A (en) 2014-11-30
CA2693863A1 (en) 2009-01-22
HRP20120949T1 (en) 2012-12-31
KR20100057010A (ko) 2010-05-28
CN101687039A (zh) 2010-03-31
EA201070150A1 (ru) 2010-08-30
HK1143523A1 (en) 2011-01-07
US20100254977A1 (en) 2010-10-07
EA019485B1 (ru) 2014-04-30
ES2395799T3 (es) 2013-02-15
AU2008277907A1 (en) 2009-01-22
EP2167128B1 (en) 2012-10-24
KR101559596B1 (ko) 2015-10-12
CA2693863C (en) 2017-10-03
CY1113493T1 (el) 2016-06-22
BRPI0815567B1 (pt) 2019-06-04
CN101687039B (zh) 2014-04-16
EP2526967A1 (en) 2012-11-28
BRPI0815567A2 (pt) 2015-02-18
ZA201001124B (en) 2010-11-24

Similar Documents

Publication Publication Date Title
ZA201001124B (en) Engineered anti-alpha v-integrin hybrid antibodies
HRP20182174T1 (hr) Anti-il-23p19 antitijela proizvedena genetičkim inženjeringom
ZA200905964B (en) Engineered anti-il-23R antibodies
GB0708002D0 (en) Antibodies
SI2200700T1 (sl) Nova protitelesa
GB0821100D0 (en) Antibodies
IL198424A0 (en) Hybrid immunoglobulins with moving parts
ZA201102119B (en) Improved antibody libraies
PT2146745E (pt) Anticorpo pentaespecífico
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
GB0718737D0 (en) Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
GB0707505D0 (en) Antibodies against il-25
GB0702888D0 (en) Novel Antibodies
IL205073A0 (en) Anti-bst2 antibody
GB0817891D0 (en) Antibodies against il-25
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
HK1126789A (en) Engineered anti-il-23r antibodies
HK1144582A (en) Engineered anti-tslpr antibodies
GB0724185D0 (en) Antibodies
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies